COVID-19 Cases News: India records JUMP in number of cases; Sputnik Light gets APPROVAL for phase 3 trials - Check important UPDATES here
COVID-19 Cases News: India recorded a jump in the number of COVID-19 cases today as the data released by the Ministry of Health and Family Welfare (MoHFW) showed that the country recorded 30,570 new cases in the last 24 hours. India recorded over 30,000 cases after four consecutive days of cases less than 30,000.
COVID-19 Cases News Today
COVID-19 Vaccine Scenario
As per the data from MoHFW, 76.57 crore vaccine doses have been administered so far under Nationwide Vaccination Drive. Furthermore, more than 5.33 crore (5,33,75,475) balance and unutilized COVID-19 vaccine doses are still available with the states and union territories to be administered. Source: Reuters
COVID-19 3rd Wave
Now, one thought that is in the minds of the people is that when will the 3rd wave of COVID-19 pandemic hit the country and what would be its impact. According to an ANI report on August 23, 2021, the National Institute of Disaster Management (NIDM) warned of a third wave peak in October in its report to the Prime Minister's Office (PMO). It has to be noted that the NIDM's report quoted Reuters' opinion survey of 40 experts that forecast that the third wave of the COVID-19 pandemic is likely to hit India between July 15, 2021, and October 13, 2021. Source: Reuters
IRDAI's takes important decision anticipating 3rd wave
Insurance regulator IRDAI ordered renewal and purchase of corona special policy for the next six months, that is, till March 31, 2022. The IRDAI had ordered the launch of special Corona Kavach Policy last year to provide relief to the common man, but the renewal of the policy was only till September 30, 2021. Now, the IRDAI had ordered renewal for another six months due to the anticipation of COVID-19 3rd wave. Source: PTI
COVID-19: Sputnik Light vaccine Phase 3 trial approval
COVID-19 vaccine Sputnik Light gets permission for phase 3 trials in India. According to an ANI report, a Subject Expert Committee (SEC) meeting held on August 5, 2021 recommended the trial condition based on the efficacy of the vaccine was also to be evaluated on the 42nd, 90th and 180th day following the second dose. Source: ANI Twitter